Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2007 | 12-2006 | 09-2006 | 06-2006 | 03-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,357 | -14,752 | -10,374 | -6,723 | -3,490 |
| Depreciation Amortization | 87 | 244 | 173 | 110 | 53 |
| Accounts receivable | -183 | 14 | 30 | 13 | 320 |
| Other Working Capital | 9,033 | 20,299 | 201 | -254 | 353 |
| Other Operating Activity | 598 | 1,274 | 895 | 576 | -38 |
| Operating Cash Flow | $6,178 | $7,080 | $-9,077 | $-6,278 | $-2,802 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -161 | -365 | -256 | -99 | -39 |
| Investing Cash Flow | $-161 | $-365 | $-256 | $-99 | $-39 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 20,764 | 18,343 | 6,301 | 2,345 | 1,279 |
| Financing Cash Flow | $20,764 | $18,343 | $6,301 | $2,345 | $1,279 |
| Beginning Cash Position | 44,189 | 19,132 | 19,132 | 19,132 | 19,132 |
| End Cash Position | 70,971 | 44,189 | 16,101 | 15,100 | 17,571 |
| Net Cash Flow | $26,782 | $25,057 | $-3,031 | $-4,032 | $-1,562 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,178 | 7,080 | -9,077 | -6,278 | -2,802 |
| Capital Expenditure | -161 | -365 | -256 | -99 | -39 |
| Free Cash Flow | 6,017 | 6,715 | -9,332 | -6,378 | -2,841 |